LYPDISO™ (MAT9001)
Outclassing the omega-3 class.
LYPDISO, our novel omega-3 fatty acid composition, has the potential to become the most impactful omega‑3 treatment for patients with elevated levels of triglycerides (TGs).
Lipid Nano-Crystal Platform
Improving the intracellular delivery of important therapeutics.
Our LNC platform enables safe, intracellular, and even orally-administered delivery of a broad range of drug therapies, including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies.
Based on our LNC technology, we have developed MAT2203 and MAT2501 – two potent treatments targeting life-threatening fungal and bacterial infections.
Matinas BioPharma to Webcast Conference Call on Q3 Results
Contact us
